[Editor’s note: This is the first in a series of articles on Zolgensma and treatments for SMA, the issues they raise, and possible discoveries to come, all drawn from recent interviews with neurologists and researchers involved in this work. Others in this series can be found here. SMA News…

Zolgensma‘s approval as the first gene therapy for treating all forms of spinal muscular atrophy (SMA) in children up to 2 years old is another step forward — an exceptional and far-reaching one — in the seeming revolution underway in treating more diseases, and an increasing number of…

The gene therapy Zolgensma (onasemnogene abeparvovec-xioi) has been newly approved to treat patients with spinal muscular atrophy (SMA) through intravenous (IV) delivery, meaning systemically. However, Novartis is also waiting on a more sweeping label, one allowing both intravenous and intrathecal (IT) delivery — that which is given via…

Zolgensma, approved for children with spinal muscular atrophy (SMA) up to 2 years old, has two claims to fame: It is both the first gene therapy ever developed to treat a neuromuscular disease, and it’s by far the world’s most expensive drug. At $2.125 million, a 60-minute intravenous…

From its very first clinical trial — using  a dose widely frowned upon — Zolgensma has had a “transformative” impact on spinal muscular atrophy (SMA) and on gene therapy as a whole, said Jerry Mendell, MD, a principal investigator across Zolgensma’s clinical program. “We did our best, I think, to make…

How Zolgensma (onasemnogene abeparvovec-xioi), the gene therapy once known as AVXS-101, came into being is a tale fairly common to basic science: An idea that progressed from cell work in the lab to experiments with animals and, ultimately, testing as a possible treatment in patients. Where Zolgensma’s story diverges from…

“Great news!” was the reaction of one SMA News Today columnist to word of a first gene therapy, Zolgensma, being approved to treat infants and children up to age 2 with spinal muscular atrophy, while others on the site’s SMA community forum called it “an amazing advancement” and “such a…

Zolgensma (onasemnogene abeparvovec-xioi), the newly approved gene therapy to treat SMA in infants and children under 2 years old, works by delivering directly to motor neurons a healthy copy of the SMN1 gene that is damaged by mutations in these patients and unable to make an essential protein. Carried…

Zolgensma, a first gene therapy for spinal muscular atrophy — and first for any chronic neurologic disease — is now an approved and potential “one-time” intravenous treatment for pre-symptomatic newborns through 2-year-olds with any type of SMA, the U.S. Food and Drug Administration (FDA) announced today, issuing an historic decision.

With the U.S. Food and Drug Administration (FDA) expected to soon decide whether Zolgensma (onasemnogene abeparvovec) can treat people with spinal muscular atrophy (SMA) type 1, clinical trials of the gene therapy are showing rapid benefits across disease types. Those gains might justify a broader label — one allowing…